newsfilter
← Latest News
GlobeNewswire·

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

  • Artiva Biotherapeutics management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 3:30 pm EDT.
  • The company's lead program, AlloNK® (AB-101), is an allogeneic, off-the-shelf NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity for B-cell depletion in autoimmune diseases.
  • AlloNK is currently being evaluated in combination with anti-CD20 antibodies for indications including refractory rheumatoid arthritis, Sjögren disease, systemic sclerosis, & myositis.
  • Artiva plans to initiate a Phase 3 registrational trial for AlloNK in refractory rheumatoid arthritis during 2026.
  • Initial clinical data have shown encouraging activity & a tolerability profile supporting outpatient administration.
  • The audio webcast of the conference presentation will be available on Artiva's investor website for 90 days.
  • Artiva is headquartered in San Diego, California.